Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Regulus Therapeutics News

    2,345 $ -7,68% -0,195 $
    In : 2,1976 € | 17.04.24 21:59:30 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DNZ4
    ISIN: US75915K3095
    US-Symbol: RGLS
    Typ: Aktie

    Regulus Therapeutics News

    21.03.24 - PR Newswire
    Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
    Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire
    12.03.24 - PR Newswire
    Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew?
    Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew? PR Newswire
    12.03.24 - PR Newswire
    Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
    Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity PR Newswire
    12.03.24 - PR Newswire
    Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...
    02.01.24 - PR Newswire
    Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
    22.11.23 - PR Newswire
    Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
    Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire
    09.11.23 - PR Newswire
    Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
    Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire
    02.11.23 - PR Newswire
    Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal ...
    19.10.23 - PR Newswire
    Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney ...
    20.09.23 - PR Newswire
    Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...
    13.09.23 - PR Newswire
    Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
    05.09.23 - PR Newswire
    Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
    Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire
    23.08.23 - PR Newswire
    Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
    Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 PR Newswire
    08.08.23 - PR Newswire
    Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
    Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire
    02.08.23 - PR Newswire
    Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
    Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire
    18.07.23 - PR Newswire
    Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
    Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference PR Newswire
    27.06.23 - PR Newswire
    Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal ...
    23.06.23 - PR Newswire
    Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
    Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors PR Newswire
    20.06.23 - PR Newswire
    Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
    Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital ...
    12.06.23 - PR Newswire
    Regulus Therapeutics Strengthens Research & Development Leadership
    Regulus Therapeutics Strengthens Research & Development Leadership PR Newswire

    Newssuche

    Videos

    newspaper
    16.04.24 0,00%
    Technical Trading: Natural Gas Long Chance
    Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »